Takeda buys Nycomed for $13.6bn
pharmafile | May 19, 2011 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Nycomed, Takeda
Takeda has acquired Swiss specialist pharma firm Nycomed, boosting its presence in emerging markets.
The deal comes in at 9.6 billion euro ($13.6 billion), but excludes Nycomed’s US dermatology business.
The announcement comes just a week after Japan’s biggest pharma firm flatly denied it was in talks with Nycomed, following rumours it had offered $12 billion for the company.
Yasuchika Hasegawa, president and chief executive of Takeda, said: “Nycomed enables Takeda to maximise the value of our portfolio and gives us an immediate strong presence in the high-growth emerging markets while doubling Takeda’s European sales.
“Nycomed’s strength in a geographically wide range of markets and its diverse talent base will be a strong driver to helping us realise our important mission of striving toward better health for patients worldwide through leading innovation in medicine.”
The majority of Takeda’s Y1.41 trillion ($17 billion) sales come from Japan and North America, with emerging markets accounting for only around 2% of its total revenue.
The purchase of the Swiss drugmaker, which is particularly strong in Latin America, Russia and the Middle East, will double Takeda’s sales in emerging markets, a target the Japanese firm set itself in 2010.
It will also increase the company’s presence in Europe and Nycomed’s Zurich HQ will provide a good base for Takeda’s operations on the continent.
Nycomed’s biggest drug is its COPD treatment Daxas (roflumilast), marketed in conjunction with Forest Labs, which is now expected to be a major source of revenue growth for Takeda.
Håkan Björklund, chief executive of Nycomed, said: “The combination of Takeda’s successful track record of innovation with Nycomed’s efficient commercialisation and manufacturing infrastructure will create a global player with a phenomenal ability to bring medicines to patients and healthcare providers around the world.”
The Swiss firm made $3.17 billion in sales last year, slightly down on 2009 by 1.8% in local currencies.
The deal is expected to be completed within the next three months, at which point Nycomed will become a wholly-owned subsidiary of Takeda.
Ben Adams
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
